Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Oral ETA antagonist ABT-627 shows signs of efficacy, safety in CHF

Sep. 30, 1999

Levosimendan improves symptoms and prolongs survival in patients with various types of HF

Sep. 30, 1999

Novel natriuretic peptide is a candidate for treating CHF

Sep. 29, 1999

Conivaptan effectively and safely reverses hyponatremia in patients with CHF

Sep. 29, 1999

Positive inotropic activity of EMD-57033 is maintained during MI

Sep. 29, 1999

Xoma reports unexpected setback in Neuprex development program

Sep. 28, 1999

Novel Na+/H+ exchange inhibitor presented at Japanese congress

Sep. 27, 1999

PST-2107, an Na+/K+-ATPase inhibitor with significant advantages over digoxin

Sep. 27, 1999

Dual NEP/ACE inhibitor attenuates left ventricular remodeling without affecting blood pressure

Sep. 27, 1999

SmithKline Beecham scientists identify urotensin-II receptor

Sep. 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...